EXO1 as a therapeutic target and prognostic biomarker in prostate cancer
Jan. 29, 2024
Researchers from Renmin Hospital of Wuhan University have published results from their work that aimed to assess the role of exonuclease 1 (EXO1) in the progression of prostate cancer (PCa). A series of bioinformatic analyses revealed that EXO1 expression was higher in PCa tissue compared to normal tissue, and that high EXO1 expression predicted poor prognosis in PCa patients.